ATE421322T1 - Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege - Google Patents

Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege

Info

Publication number
ATE421322T1
ATE421322T1 AT04725360T AT04725360T ATE421322T1 AT E421322 T1 ATE421322 T1 AT E421322T1 AT 04725360 T AT04725360 T AT 04725360T AT 04725360 T AT04725360 T AT 04725360T AT E421322 T1 ATE421322 T1 AT E421322T1
Authority
AT
Austria
Prior art keywords
quinolin
derivatives
treatment
respiratory diseases
compounds
Prior art date
Application number
AT04725360T
Other languages
English (en)
Inventor
R A Fairhurst
D A Sandham
David Beattie
Ian Bruce
Bernard Cuenoud
Reamonn Madden
Neil John Press
Roger J Taylor
Katharine L Turner
Simon J Watson
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0307856A external-priority patent/GB0307856D0/en
Priority claimed from GB0311462A external-priority patent/GB0311462D0/en
Priority claimed from GB0313489A external-priority patent/GB0313489D0/en
Priority claimed from GB0316657A external-priority patent/GB0316657D0/en
Priority claimed from GB0316656A external-priority patent/GB0316656D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE421322T1 publication Critical patent/ATE421322T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04725360T 2003-04-04 2004-04-02 Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege ATE421322T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0307856A GB0307856D0 (en) 2003-04-04 2003-04-04 Organic compounds
GB0311462A GB0311462D0 (en) 2003-05-19 2003-05-19 Organic compounds
GB0313489A GB0313489D0 (en) 2003-06-11 2003-06-11 Organic compounds
GB0316657A GB0316657D0 (en) 2003-07-16 2003-07-16 Organic compounds
GB0316656A GB0316656D0 (en) 2003-07-16 2003-07-16 Organic compounds

Publications (1)

Publication Number Publication Date
ATE421322T1 true ATE421322T1 (de) 2009-02-15

Family

ID=33136224

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725360T ATE421322T1 (de) 2003-04-04 2004-04-02 Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege

Country Status (13)

Country Link
US (1) US7745462B2 (de)
EP (1) EP1613315B1 (de)
JP (1) JP4516064B2 (de)
AT (1) ATE421322T1 (de)
AU (1) AU2004226824B2 (de)
BR (1) BRPI0409198A (de)
CA (1) CA2521271C (de)
DE (1) DE602004019198D1 (de)
ES (1) ES2320994T3 (de)
MX (1) MXPA05010712A (de)
PL (1) PL1613315T3 (de)
PT (1) PT1613315E (de)
WO (1) WO2004087142A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1917253B1 (de) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
EP2532677A1 (de) 2005-10-21 2012-12-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1878722A1 (de) * 2006-07-13 2008-01-16 Novartis AG Chinolinonderivate und ihre pharmazeutischen Zusammensetzungen
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CN101230058A (zh) * 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
RU2487866C2 (ru) * 2008-01-23 2013-07-20 Цзянсу Хэнсох Фармасьютикал Ко., Лтд. Производные дициклоазаалкана, способы их получения и их применение в медицине
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CA2819510A1 (en) * 2010-12-22 2012-06-28 Onyx Pharmaceuticals, Inc. Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta(g)quinazoline trisodium salt
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
CN104470927B (zh) * 2013-06-07 2016-05-04 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
CN103408465B (zh) * 2013-07-29 2015-08-26 南开大学 一种n-二取代苯基甲基缬氨酰胺氨基甲酸酯衍生物及应用
WO2016038628A2 (en) * 2014-09-09 2016-03-17 Reddy G Pratap A process for preparing olodaterol and intermediates thereof
SI3216790T1 (sl) * 2014-11-05 2020-02-28 Jiangsu Hengrui Medicine Co., Ltd., Kristalinična oblika bisulfata inhibitorja JAK-kinaze in postopek priprave le-te
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US10947196B2 (en) 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物
EP3993878A4 (de) * 2019-07-01 2023-11-08 Curasen Therapeutics, Inc. Beta-adrenerger agonist und verfahren zu seiner verwendung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6026784B2 (ja) * 1975-04-29 1985-06-25 樋口 佳成 新規カルボスチリル誘導体
JPS597706B2 (ja) * 1975-06-13 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS597707B2 (ja) * 1975-06-23 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノ セイゾウホウ
JPS57154129A (en) * 1981-03-16 1982-09-22 Otsuka Pharmaceut Co Ltd Cardiotonic drug
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPS6010032B2 (ja) * 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体
JPS6010033B2 (ja) * 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体の製造法
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物

Also Published As

Publication number Publication date
JP4516064B2 (ja) 2010-08-04
MXPA05010712A (es) 2005-12-15
AU2004226824A1 (en) 2004-10-14
EP1613315A1 (de) 2006-01-11
DE602004019198D1 (de) 2009-03-12
US7745462B2 (en) 2010-06-29
ES2320994T3 (es) 2009-06-01
JP2006523190A (ja) 2006-10-12
CA2521271A1 (en) 2004-10-14
CA2521271C (en) 2011-01-04
BRPI0409198A (pt) 2006-05-02
AU2004226824B2 (en) 2008-05-01
PL1613315T3 (pl) 2009-07-31
US20070066607A1 (en) 2007-03-22
EP1613315B1 (de) 2009-01-21
WO2004087142A1 (en) 2004-10-14
PT1613315E (pt) 2009-04-22

Similar Documents

Publication Publication Date Title
DE602004019198D1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
GB0305152D0 (en) Organic compounds
MY135050A (en) Organic compounds
MY156407A (en) 5-phenylthiazole derivatives and use as p13 kinase inhibitors
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
TNSN05278A1 (en) Inhibitors of phosphatidylinositol 3-kinase
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE326466T1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
EA201070543A1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
MXPA04000036A (es) Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
MY146802A (en) Novel drugs for treating respiratory diseases
WO2007068473A3 (en) Organic compounds
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1613315

Country of ref document: EP